US FTC says Amgen can't avoid antitrust scrutiny for acquisition of patent applications
MLex Summary The US Federal Trade Commission told the Court of Appeals for the Fourth Circuit that acquisitions of patent applications are not categorically immune from antitrust scrutiny, and such acquisitions...To view the full article, register now.
Already a subscriber? Click here to view full article